NASDAQ:FGEN
FibroGen Stock News
$1.14
+0.0100 (+0.88%)
At Close: May 03, 2024
AstraZeneca and FibroGen face FDA red light over anaemia drug
02:35am, Friday, 16'th Jul 2021
AstraZeneca PLC (LON:AZN) is facing rejection from the US drug regulator for its application for a novel new drug to treat anaemia resulting from chronic kidney disease. The Food and Drug Administrati
FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease
06:26pm, Thursday, 15'th Jul 2021
SAN FRANCISCO, July 15, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC
What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict
05:04pm, Wednesday, 14'th Jul 2021
FibroGen, Inc. (NASDAQ:FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the company's new drug application for roxadustat
Ahead Of AdComm AstraZeneca, FibroGen's Roxadustat Hit With Safety, Efficacy Questions
01:03pm, Tuesday, 13'th Jul 2021
Ahead of Thursday's meeting of the FDA's Cardiovascular and Renal Drugs Advisory Committee, the agency is raising fresh doubts on the safety of AstraZeneca Plc's (NASDAQ: AZN) and FibroGen Inc's (
FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer
07:00am, Monday, 12'th Jul 2021
SAN FRANCISCO, July 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific Officer, where he will lead FibroGen
European Regulators Suggest Approval of FibroGen's Key Drug
10:29am, Friday, 25'th Jun 2021
European regulators issued a positive recommendation on FibroGen's key drug roxadustat, which has had major setbacks in its path to approval in the U.S.
TOKYO, June 25, 2021 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") t
SAN FRANCISCO and CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN) and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with exper
Pamrevlumab Included in Pancreatic Cancer Action Network's Adaptive Clinical Trial Platform
08:00am, Wednesday, 16'th Jun 2021
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision Promise SM adapt
New York, New York--(Newsfile Corp. - June 12, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certai
Los Angeles, California--(Newsfile Corp. - June 11, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against Fib
Final Day to Actively Participate: FibroGen, Inc. (FGEN) Class Action - Bronstein, Gewirtz & Grossman, LLC
10:00am, Friday, 11'th Jun 2021
New York, New York--(Newsfile Corp. - June 11, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or "the Compa
NEW YORK, June 10, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its offic
FibroGen Class Action Reminder
07:25pm, Thursday, 10'th Jun 2021
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile C
New York, New York--(Newsfile Corp. - June 10, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging tha
